Attached files

file filename
EX-31.1 - EXHIBIT 31.1 - CEO - Animal Health International, Inc.exhibit31_1.htm
EX-32.1 - EXHIBIT 32.1 - Animal Health International, Inc.exhibit32_1.htm
EX-31.2 - EXHIBIT 31.2 - CFO - Animal Health International, Inc.exhibit31_2.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 10-Q
 
x
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the quarterly period ended December 31, 2009
 
OR
 
¨
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
Commission File Number 1-33273
 
 ANIMAL HEALTH INTERNATIONAL, INC.
(Exact name of Registrant as specified in its charter)
 
 
Delaware
 
71-0982698
(State or other jurisdiction of
incorporation or organization)
 
(I.R.S. Employer
Identification Number)
 
7 Village Circle, Suite 200
Westlake, Texas
 
76262
(Address of principal executive offices)
 
(Zip Code)
 
Registrant’s telephone number, including area code: (817) 859-3000
 
    Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes   x     No   ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes    o     No    o
  
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or smaller reporting company.  See the definitions of “large accelerated filer”, “accelerated filer”, and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
 
Large Accelerated Filer   ¨     Accelerated Filer   ¨      Non-Accelerated Filer   ¨   Smaller Reporting Company x
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes   ¨     No   x
 
As of January 21, 2010, 24,329,670 shares of the registrant’s common stock were outstanding.
 
 ANIMAL HEALTH INTERNATIONAL, INC.
FORM 10-Q
FOR THE QUARTERLY PERIOD ENDED DECEMBER 31, 2009
 
TABLE OF CONTENTS
 
   
Page
 
     
     
    2  
    2  
    3  
    4  
    5  
    6  
         
    14  
         
    21  
         
    21  
         
    22  
         
    22  
         
    22  
         
    22  
         
    22  
         
    22  
         
    22  
         
    22  
         
    22  
EX-31.1: CERTIFICATION
       
EX-31.2: CERTIFICATION
       
EX-32.1: CERTIFICATION
       
 
 
 

 
 
PART 1. FINANCIAL INFORMATION
 
 Item 1.
Financial Statements
Consolidated Financial Statements
 
 ANIMAL HEALTH INTERNATIONAL, INC.
Consolidated Balance Sheets
(In thousands, excluding share information)
  (Unaudited)  
   
  
June 30,
2009
   
December 31, 2009
 
Assets
  
             
Current assets:
  
             
Cash and cash equivalents
  
$
2,749
   
$
2,085
 
Accounts receivable, net
  
 
74,441
     
82,596
 
Current portion of notes receivable
  
 
126
     
204
 
Income tax receivable
  
 
1,001
     
1,777
 
Merchandise inventories, net
  
 
89,315
     
102,350
 
Deferred income taxes
  
 
3,358
     
3,463
 
Prepaid expenses
  
 
2,319
     
1,730
 
Total current assets
  
 
173,309
     
194,205
 
     
Noncurrent assets:
  
             
Notes receivable, net of current portion
  
 
280
     
171
 
Property, plant, and equipment, net
  
 
16,043
     
15,556
 
Goodwill
  
 
60,334
     
62,245
 
Customer relationships
  
 
28,022
     
26,319
 
Noncompete agreements
  
 
3,436
     
2,898
 
Trademarks and trade names
  
 
33,170
     
33,170
 
Debt issue costs and other assets, net of accumulated amortization of $2,017
and $2,537, respectively
  
 
3,671
     
3,189
 
Total assets
  
$
318,265
   
$
337,753
 
 
  
             
Liabilities and Stockholders’ Equity
  
             
Current liabilities:
  
             
Accounts payable
  
$
83,567
   
$
86,768
 
Accrued liabilities
  
 
13,055
     
15,151
 
Current portion of long-term debt
  
 
7,179
     
457
 
Total current liabilities
  
 
103,801
     
102,376
 
     
Noncurrent liabilities:
  
             
Long-term debt, net of current portion
  
 
119,913
     
137,150
 
Deferred lease incentives
  
 
1,101
     
1,154
 
Deferred income taxes
  
 
23,069
     
23,624
 
Total liabilities
  
 
247,884
     
264,304
 
 
  
             
Commitments and contingencies (note 12)
  
             
     
Stockholders’ equity:
  
             
Preferred stock, par value $0.01 per share. Authorized 10,000,000 shares,
    issued and outstanding 0 shares
  
 
     
 
Common stock, par value $0.01 per share. Authorized 90,000,000 shares,
    issued and outstanding 24,329,670 shares
  
 
243
     
243
 
Additional paid-in capital
  
 
132,912
     
133,157
 
Accumulated deficit
  
 
(58,853
)
   
(58,382
)
Accumulated other comprehensive loss
  
 
(3,921
)
   
(1,569
)
Total stockholders’ equity
  
 
70,381
     
73,449
 
 
  
             
Total liabilities and stockholders’ equity
  
$
318,265
   
$
337,753
 
 
See accompanying Notes to Unaudited Consolidated Financial Statements.
 
2

 
 
 
 ANIMAL HEALTH INTERNATIONAL, INC.
Consolidated Statements of Operations
(In thousands, except per share data)
(Unaudited)
 
 
 
  
Three Months Ended
December 31,
   
Six Months Ended
December 31,
 
 
  
2008
   
2009
   
2008
   
2009
 
Net sales
  
$
184,477
   
$
170,487
   
$
353,500
   
$
331,816
 
Costs and expenses:
  
                             
Direct cost of products sold (excludes depreciation and amortization)
  
 
152,209
     
141,071
     
290,932
     
276,454
 
Salaries, wages, commissions, and related benefits
  
 
11,818
     
12,722
     
26,149
     
25,561
 
Selling, general, and administrative
  
 
12,579
     
10,818
     
23,866
     
20,767
 
Depreciation and amortization
  
 
2,054
     
2,022
     
4,130
     
4,000
 
Operating income
  
 
5,817
     
3,854
     
8,423
     
5,034
 
         
Other income (expense):
  
                             
Other income
  
 
189
     
166
     
418
     
300
 
Interest expense
  
 
(2,289
)
   
(2,068
)
   
(4,623
)
   
(4,579
)
Income before income taxes
  
 
3,717
     
1,952
     
4,218
     
755
 
Income tax expense
  
 
(1,448
)
   
(734
)
   
(1,665
)
   
(284
)
Net income
  
$
2,269
   
$
1,218
   
$
2,553
   
$
471
 
                                 
Earnings per common share:
  
                             
Basic
  
$
0.09
   
$
0.05
   
$
0.10
   
$
0.02
 
Diluted
  
$
0.09
   
$
0.05
   
$
0.10
   
$
0.02
 
Weighted average shares outstanding:
  
                             
Basic
  
 
24,330
     
24,330
     
24,330
     
24,330
 
Diluted
  
 
24,330
     
24,330
     
24,330
     
24,330
 
 
See accompanying Notes to Unaudited Consolidated Financial Statements.
  
 
 
3

 

 
ANIMAL HEALTH INTERNATIONAL, INC.
Consolidated Statements of Comprehensive Income (Loss)
(In thousands)
(Unaudited)
 
 
  
Three months ended
December 31,
   
Six months ended
December 31,
 
 
  
2008
   
2009
   
2008
   
2009
 
Net income
  
$
2,269
   
$
1,218
   
$
2,553
   
$
471
 
         
Other comprehensive income (loss):
  
                             
Unrealized gain (loss) on derivative instruments, net of tax
  
 
(1,392
)
   
993
     
(1,331
)
   
1,336
 
Foreign currency translation adjustment
  
 
(1,006
)
   
325
     
(1,316
   
1,016
 
 
  
                             
Total comprehensive income (loss)
  
$
(129
 
$
2,536
   
$
(94
 
$
2,823
 
 
  
                             
 
See accompanying Notes to Unaudited Consolidated Financial Statements.
 
 
 
4

 
 
ANIMAL HEALTH INTERNATIONAL, INC.
Consolidated Statements of Cash Flows
(In thousands)
(Unaudited)
 
  
Six Months Ended
 
 
  
December 31,
 
 
  
2008
   
2009
 
Cash flows from operating activities :
  
             
Net income
  
$
2,553
   
$
471
 
Adjustments to reconcile net income to net cash provided by (used for) operating activities:
  
             
Depreciation and amortization
  
 
4,130
     
4,000
 
Amortization of debt issue costs
  
 
338
     
520
 
Amortization of loss on settlement of interest rate swap agreements
   
     
620
 
Bad debt expense
   
23
     
203
 
Stock compensation expense
  
 
684
     
245
 
Gain on sale of equipment
  
 
(101
)
   
(15
)
Deferred income taxes
  
 
(877
)
   
221
 
Changes in operating assets and liabilities (working capital):
  
             
Accounts receivable
  
 
(6,772
)
   
(8,792
)
Merchandise inventories
  
 
(2,001
)
   
(12,139
)
Income taxes receivable/payable
  
 
1,117
     
(152
Prepaid expenses
  
 
495
     
604
 
Accounts payable
  
 
2,374
     
7,470
 
Accrued liabilities and other
  
 
(105
)
   
(633
 
  
             
Net cash provided by (used for) operating activities
  
 
1,858
     
(7,377
     
Cash flows from investing activities:
  
             
Purchase of property, plant, and equipment
  
 
(1,751
)
   
(1,229
)
Disposition (purchase) of other assets
  
 
104
     
(221
Purchase price adjustments
  
 
(2,856
)
   
 
Proceeds from sale of equipment
  
 
284
     
103
 
Net changes in notes receivable
  
 
301
     
76
 
 
  
             
Net cash used for investing activities
  
 
(3,918
)
   
(1,271
)
     
Cash flows from financing activities:
  
             
Repayment of long-term debt
  
 
(635
)
   
(2,874
)
Settlement of terminated interest rate swap agreements
   
     
(3,348
)
Net borrowings under revolving credit facilities
  
 
3,076
     
17,308
 
Debt issue costs
  
 
(39
)
   
(63
)
Change in overdraft balances
  
 
4,759
     
(2,915
 
  
             
Net cash provided by financing activities
  
 
7,161
     
8,108
 
     
Effect of exchange rate changes on cash and cash equivalents
  
 
(72
   
(124
 
  
             
Net increase (decrease) in cash and cash equivalents
  
 
5,029
     
(664
     
Cash and cash equivalents, beginning of period
  
 
2,452
     
2,749
 
 
  
             
Cash and cash equivalents, end of period
  
$
7,481
   
$
2,085
 
 
See accompanying Notes to Unaudited Consolidated Financial Statements.
 
 
5

 
 
 ANIMAL HEALTH INTERNATIONAL, INC.
Notes to consolidated financial statements
(Dollars in thousands, except share and per share data)
(Unaudited)
 
(1) Organization
 
Animal Health International, Inc. (AHII), was incorporated in Delaware in May 2005. Through its wholly-owned subsidiaries, Walco International, Inc. and Kane Veterinary Supplies, Ltd. (Kane, note 3, collectively, with AHII, the Company), the Company’s primary business activity is the sale and distribution of animal health products, supplies, services and technology through operating divisions located throughout the United States, Canada and Taiwan.
 
(2) Summary of significant accounting policies
 
(a) Basis of consolidation
 
The accompanying unaudited consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
 
In the opinion of management, the accompanying unaudited consolidated financial statements include all adjustments necessary to present fairly, in all material respects, the results of the Company for the periods presented. These consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes for the year ended June 30, 2009 included in the Company’s Annual Report on Form 10-K. The results of operations for the three and six months ended December 31, 2009 are not necessarily indicative of results to be expected for the entire fiscal year.
 
(b) Rebates
 
Inventory rebates are recognized when estimable and probable and include inventory purchase rebates and sales-related rebates. Inventory purchase rebates received are capitalized into inventory while sales-related rebates are recorded as a reduction of direct cost of products sold.
 
(c) Stock compensation
 
In January 2007, the Company reserved 2,500,000 shares of its common stock for the issuance of awards under the 2007 Stock Option and Incentive Plan.  In November 2009, the Company amended and restated the 2007 Stock Option and Incentive Plan, and reserved an additional 1,100,000 shares of its common stock for the issuance of awards.
 
In January 2007, the Company issued options to purchase an aggregate of 749,300 shares under terms established by the 2007 Stock Option and Incentive Plan. The Company also issued options to purchase 9,500 shares in May 2007, an additional 750,000 shares in both November 2007 and November 2008, and 411,125 in December 2009.  The options vest over a four-year period, carry a ten-year term, and have an exercise price of $11.00 per share for the initial 749,300 shares, $13.53 per share for the 9,500 shares granted in May 2007, $11.47 per share for the 750,000 shares granted in November 2007, $2.37 per share for the 750,000 shares granted in November 2008, and $2.65 per share for the 411,125 shares granted in December 2009. The options issued are incentive stock options, which are not performance-based and vest with continued employment. Unexercised options may be forfeited in the event of termination of employment. Options to purchase 341,087 shares were vested and had a weighted average exercise price of $6.81, and a weighted average remaining contract term of 8.1 years, but no options were exercised as of December 31, 2009.   In December 2009, the Company issued 838,875 restricted stock units to certain employees. These units vest over a four-year period, have an indefinite life, and convert to shares of common stock upon certain triggering events. The units carried a fair value of $2.15 upon their issuance, and the expense related to these units during the three months ended December 31, 2009 was $30.
 
6

During May 2009, the Company’s senior management voluntarily surrendered 1,018,500 options for no consideration. The voluntary surrender was not accompanied by a concurrent grant of a replacement award nor any other valuable consideration. Accordingly, the unrecognized compensation expense related to these stock options of $1,803 was recognized as compensation expense in the fourth quarter of fiscal 2009. After accounting for the 838,875 restricted stock units granted to employees, the 360,720 deferred stock units granted to non-employee members of the Board of Directors, and the 1,381,112 stock options issued to employees that have not been forfeited or surrendered, there were 1,019,293 shares of common stock reserved for future issuance at December 31, 2009.
 
The Company uses the Black-Scholes formula to estimate the value of stock options granted to employees and expects to continue to use this option valuation model. The Company includes a forfeiture estimate in the amount of compensation expense being recognized. The forfeiture estimate is based on historical employee turnover rates. The estimated fair value of the options is amortized to expense on a straight-line basis over the four-year vesting period.
 
Total compensation expense for these options and restricted stock units is $7,515 including the following amounts charged or to be charged to compensation expense each year ended June 30 over each four-year vesting period: $224 in 2007, $1,342 in 2008, $3,208 in 2009, $673 in 2010, $801 in 2011, $612 in 2012, $473 in 2013, and $182 in 2014. Compensation expense related to these options and restricted stock units totaled $350 and $140 for the three months ended December 31, 2008 and 2009, respectively, and $684 and $245 for the six months ended December 31, 2008 and 2009, respectively. The weighted average remaining contract term for the options was 8.9 years at December 31, 2009.
 
A summary of stock option activity is as follows: 
 
   
Options
   
Weighted Average
Exercise Prices
   
Weighted Average Fair
Value at Grant Date
 
Balance at July 1, 2009
   
1,014,175
   
 $
5.03
     
1.81
 
Granted
   
411,125
     
2.65
     
0.88
 
Exercised
   
     
     
 
Forfeited
   
(44,188
)
   
3.62
     
1.23
 
                         
Balance at December 31, 2009
   
1,381,112
   
$
4.33
   
$
1.53
 

Intrinsic value for stock options is defined as the difference between the current market value and the exercise price. The aggregate intrinsic value for these stock options was $20 at December 31, 2009.

(d) Earnings per share
 
Earnings per share reflects application of the two class method. All classes of common stock participate pro rata in dividends. Therefore, the two class method of calculating earnings per share has been applied. Basic earnings per share is computed by dividing net income available to common shareholders by the weighted average number of common shares outstanding for the reporting period. Diluted earnings per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. For the calculation of diluted earnings per share, the basic weighted average number of shares is increased by the dilutive effect of stock options determined using the treasury stock method. The components of basic and diluted earnings per share are as follows (in thousands, except per share amounts):
 
 
Three Months Ended
December 31,
 
Six Months Ended
December 31,
 
 
2008
 
2009
 
2008
 
2009
 
Net income available to common shareholders
  $ 2,269     $ 1,218     $ 2,553     $ 471  
Basic weighted average shares outstanding
    24,330       24,330       24,330       24,330  
Dilutive effect of stock options
                       
                                 
Diluted weighted average shares outstanding
    24,330       24,330       24,330       24,330  
                           
Basic earnings per share
  $ 0.09     $ 0.05     $ 0.10     $ 0.02  
                                 
Diluted earnings per share
  $ 0.09     $ 0.05     $ 0.10     $ 0.02  
 
 
7

 


 
(e) Effect of recently issued accounting pronouncements

A recent pronouncement by the Financial Accounting Standards Board (FASB) defines fair value, establishes a framework for measuring fair value in accordance with Generally Accepted Accounting Principles (GAAP), and expands disclosures about fair value measurements. The provisions of this pronouncement were adopted on a prospective basis for financial instruments in the first quarter of fiscal 2009 and had no impact upon the Company’s consolidated financial statements. Those provisions relate to financial assets and liabilities carried at fair value and fair value disclosures related to financial assets and liabilities. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.  The provisions of the pronouncement for nonfinancial assets and nonfinancial liabilities became effective for the Company in the first quarter of fiscal 2010 and had no impact upon the Company’s consolidated financial statements.
 
A recent FASB pronouncement establishes principles and requirements for how an acquirer in a business combination recognizes and measures in its financial statements the identifiable assets acquired, the liabilities assumed, and any controlling interest; recognizes and measures the goodwill acquired in the business combination or a gain from a bargain purchase; and determines what information to disclose to enable users of the financial statements to evaluate the nature and financial effects of the business combination. The pronouncement became effective for the Company in the first quarter of fiscal 2010. The impact that the pronouncement will have on future consolidated financial statements will vary with each future acquisition.
 
In June 2009, the FASB released a Codification, which establishes the FASB Accounting Standards Codification as the source of authoritative accounting principles recognized by the FASB to be applied in the preparation of financial statements in conformity with GAAP. This Codification explicitly recognizes rules and interpretive releases of the SEC under federal securities laws as authoritative GAAP for SEC registrants. The Codification became effective September 15, 2009, and did not have an impact upon the Company’s consolidated financial statements.
 
(3) Acquisitions
 
The Company acquired certain assets of Farm City Animal Supply, Inc. during the second fiscal quarter of 2007. Cash of $105 was paid during the quarter ended September 30, 2008, as an earn-out payment to certain selling stockholders of Farm City Animal Supply, Inc. During the quarter ended December 31, 2008, the Company received $74 in cash proceeds as a final settlement on the acquisition. The earn-out payment and settlement proceeds comprise a net $31 in purchase price adjustments that were accounted for as goodwill.
 
In October 2007, AHII acquired all of the outstanding stock of Kane for $22,184 in cash (plus $1,017 in direct acquisition costs). In addition, the Company is obligated to make additional cash payments to certain selling stockholders if certain performance targets are met through October 2010. Substantially all of these contingent payments, if any, will be accounted for as goodwill when and if earned. Kane is based in Edmonton, Canada, and is a leading distributor of animal health products in both the production and companion animal markets. During the quarter ended December 31, 2008, certain performance targets were met, and the Company paid $2,825 to certain selling stockholders in the same quarter. During the quarter ended December 31, 2009, certain performance targets were met, and in January of 2010, the Company paid $1,911 to certain selling stockholders. Both of these purchase price adjustments were accounted for as goodwill in the quarter earned.

The Company’s acquisitions serve to further the Company’s strategy to access additional product lines, sales representatives, customer opportunities, manufacturer relationships and sales territories.
 
8

(4) Accounts receivable, net
 
 
  
June 30,
2009
   
December 31,
2009
 
Trade accounts receivable
  
$
68,494
   
$
76,366
 
Vendor rebate receivables
  
 
8,239
     
9,380
 
Other receivables
  
 
1,116
     
418
 
 
  
             
 
  
 
77,849
     
86,164
 
Less allowance for doubtful accounts
  
 
(3,408
)
   
(3,568
)
 
  
             
Accounts receivable, net
  
$
74,441
   
$
82,596
 
 
At June 30, 2009, the Company recorded a bad debt provision of $2,708 as a result of a dispute with a manufacturer regarding a rebate receivable. This receivable remained in dispute at December 31, 2009.
 
(5) Property, plant, and equipment, net
 
 
  
June 30,
2009
   
December 31,
2009
 
Land
  
$
3,461
   
$
3,461
 
Buildings and improvements
  
 
4,378
     
4,434
 
Leasehold improvements
  
 
3,749
     
3,842
 
Construction in progress
  
 
26
     
 
Equipment:
  
             
Warehouse
  
 
2,359
     
2,460
 
Automotive
  
 
6,730
     
6,804
 
Office/software
  
 
5,392
     
5,947
 
 
  
             
 
  
 
26,095
     
26,948
 
Less accumulated depreciation
  
 
(10,052
)
   
(11,392
)
 
  
             
Property, plant, and equipment, net
  
$
16,043
   
$
15,556
 
 
Depreciation expense was $915 and $901 for the three months ended December 31, 2008 and 2009, respectively, and $1,766 and $1,759 for the six months ended December 31, 2008 and 2009, respectively.
 
9

 
(6) Goodwill and other intangible assets
 
 
Estimated
Useful Life
 
Gross
Carrying
Amount
   
Accumulated
Amortization
   
Net
Carrying
Amount
 
June 30, 2009 :
                   
Goodwill
 Indefinite
 
$
60,334
   
$
   
$
60,334
 
Customer relationships
 12 years
   
40,578
     
(12,556
)
   
28,022
 
Noncompete agreements
 2-5 years
   
6,245
     
(2,809
)
   
3,436
 
Trademarks and trade names
 Indefinite
   
33,170
     
     
33,170
 
                           
     
$
140,327
   
$
(15,365
)
 
$
124,962
 
                           
December 31, 2009 :
                         
Goodwill
  Indefinite
 
$
62,245
   
$
   
$
62,245
 
Customer relationships
 12 years
   
40,578
     
(14,259
)
   
26,319
 
Noncompete agreements
 2-5 years
   
6,245
     
(3,347
)
   
2,898
 
Trademarks and trade names
 Indefinite
   
33,170
     
     
33,170
 
                           
     
$
142,238
   
$
(17,606
)
 
$
124,632
 
 
Amortization expense related to intangible assets totaled $1,139 and $1,121 for the three months ended December 31, 2008 and 2009, respectively, and $2,364 and $2,241 for the six months ended December 31, 2008 and 2009, respectively. Based on the current estimated useful lives assigned to intangibles assets, amortization expense for fiscal 2010, 2011, 2012, 2013, and 2014 is projected to total $4,482, $4,482, $4,229, $3,867, and $3,406, respectively.
 
The Company reviews its goodwill and other nonamortizing intangible assets for impairment annually at the close of the fiscal year or more frequently if indicators of impairment exist. A significant amount of judgment is involved in determining if an indicator of impairment has occurred. Such indicators may include, among others: a significant decline in the Company’s expected future cash flows; a sustained, significant decline in the Company’s stock price and market capitalization; a significant adverse change in legal factors or in the business climate; unanticipated competition; and slower growth rates. Any adverse change in these factors could have a significant impact on the recoverability of the Company’s goodwill and other nonamortizing intangible assets and could have a material impact on the Company’s consolidated financial statements.
 
The Company’s stock price and market capitalization have improved in the past six months, and the Company has experienced minimal change in growth rates in the past six months. As a result, the Company concluded that indicators had not emerged to indicate that impairment testing needed to be performed as of December 31, 2009. The Company will perform its annual impairment test at June 30, 2010.
 
(7) Long-term debt
 
 
  
June 30,
2009
   
December 31,
2009
 
Credit agreement—Revolving credit facility
  
$
79,245
   
$
96,553
 
Credit agreement—Term Note
  
 
43,650
     
41,045
 
Liability for interest rate swap agreements
   
3,920
     
 
Other
  
 
277
     
9
 
 
  
             
 
  
 
127,092
     
137,607
 
Less current portion
  
 
(7,179
)
   
(457
)
 
  
             
 
  
$
119,913
   
$
137,150
 
 
10


In August 2007, the Company entered into a new $44,550 first lien term loan and with borrowings thereunder paid in full the $44,550 balance of our then existing $45,000 first lien term loan. The $44,550 first lien term loan matures on May 31, 2011 and bears interest at an annual rate equal to LIBOR plus 2.0%, which is paid quarterly. Borrowings are collateralized by a first priority interest in and lien on all of the Company’s assets.
 
In October 2007, the revolving credit facility (the Revolver) was amended to a $135,000 facility, which matures on June 30, 2010. The amended Revolver included a $10,000 overcollateralization first drawn sub-limit that amortizes and expired on March 31, 2009. The outstanding borrowings under the $10,000 overcollateralization first drawn sub-limit bore interest at the rate of 0.75% above the rate as defined per the terms of the September 2006 Revolver amendment. The outstanding borrowings under the Revolver’s base $135,000 facility bore interest at the rate defined per the terms of the September 2006 Revolver amendment.

In May 2009, the Revolver was amended to a $130,000 facility, with maturity on the earlier of June 30, 2012, or 60 days prior to the final extended maturity date of the Term Note, which currently matures on May 31, 2011. The outstanding borrowings under the amended facility bear interest through July 20, 2009, at LIBOR plus 3.50% for U.S. borrowings and CDOR Rate plus 1% for Canadian borrowings, and thereafter at rates based upon the Company’s Leverage Ratio as defined in the amended Revolver with LIBOR-based rates ranging from LIBOR and CDOR Rate plus 3.00% to LIBOR and CDOR Rate plus 3.75%, and with Prime-based rates ranging from U.S. Prime and Canadian Prime Rate plus 0.50% to U.S. Prime and Canadian Prime Rate plus 1.25%. Debt issue costs of $1,098 resulting from this extension were capitalized and are being amortized over the remaining term of the Revolver utilizing the straight-line method, which approximates the effective interest method.  Borrowings remain collateralized by a first priority interest in and lien on all of the Company’s assets. At December 31, 2009, the Company’s availability under the Revolver totaled $29,069.
 
As of December 31, 2009, the interest rates for the Revolver ranged from 3.80% to 4.25%, and the interest rate for the first lien term loan was 2.25%. Additionally, the Company is required to pay a commitment fee on the daily unused amount of the Revolver at a per annum rate of 0.50%. The credit agreements contain certain covenants that, among other things, restrict our ability to incur additional indebtedness, make certain payments, sell assets, enter into certain transactions with affiliates and create liens. Moreover, certain of these agreements require us to maintain specified financial ratios. The most restrictive covenant relates to the creation or assumption of additional indebtedness. The Company was in compliance with all financial covenants at December 31, 2009.

The Company has utilized cash flow hedge accounting and used derivative financial instruments to effectively convert a portion of its variable-rate debt to fixed-rate debt. Based upon interest rates, in order to reduce cash interest expense over the last three quarters of fiscal 2010, the Company elected to terminate both of its interest rate swap agreements as of September 30, 2009.

The Company entered into a $43,000 notional value swap transaction with a financial institution effective April 18, 2007. The Company received a floating rate based on LIBOR and paid a fixed rate of 4.95%. The swap agreement had an original termination date of June 28, 2010. On September 30, 2009, the Company terminated the swap agreement, and the fair value of this swap was a net liability of $1,511 on that date. This liability was paid in October 2009.
 
The Company entered into a $52,000 million notional value swap transaction with a financial institution effective April 18, 2007. The Company received a floating rate based on LIBOR and paid a fixed rate of 4.95%. The swap agreement had an original termination date of May 7, 2010. On September 30, 2009, the Company terminated the swap agreement, and the fair value of this swap was a net liability of $1,837 on that date. This liability was paid in October 2009.
 
Swap agreement fair values are recorded on the consolidated balance sheet as a component of current portion of long-term debt. The fair values of the interest rate swap agreements were estimated based on current settlement prices and quoted market prices of comparable contracts. The Company calculated no ineffectiveness on both interest rate swap agreements at their termination on September 30, 2009. At December 31, 2009, an unrealized loss of $1,016, net of taxes of $677, is recorded on the consolidated balance sheet as accumulated other comprehensive income (loss). This unrealized loss will be amortized to interest expense over the remaining terms of the original swap agreements.

 
11

 
 
The net receipts or payments from the interest rate swap agreements were recorded in interest expense. During the three months ended December 31, 2008, changes in the fair values of interest rate swap agreements totaled $(2,320). During the six months ended December 31, 2008 and 2009, changes in the fair value of interest rate swap agreements totaled $(2,218) and $572, respectively. The Company reclassified $447 during the three months ended December 31, 2008, and $968 and $1,047, respectively, during the six months ended December 31, 2008 and 2009, from accumulated other comprehensive income (loss) to interest expense. 
 
(8) Financial instruments
 
The fair value hierarchy prioritizes inputs to valuation techniques based on observable and unobservable data and categorizes the inputs into three levels:  Level 1 – Unadjusted quoted prices in active markets for identical assets or liabilities, Level 2 – Significant observable pricing inputs other than quoted prices included within Level 1 that are either directly or indirectly observable as of the reporting date (essentially, this represents inputs that are derived principally from or corroborated by observable market data), and Level 3 – Generally unobservable inputs, which are developed based on the best information available and may include the Company’s own internal data.  Observable data should be used when available.

The following table presents the Company’s financial assets and liabilities measured as of December 31, 2009:
 
         
Fair Value
 
   
December 31,
2009
   
Level 1
   
Level 2
   
Level 3
 
Financial assets at cost:
                       
Current portion of notes receivable
 
$
204
                   
Notes receivable, net of current portion
   
171
                   
Total
 
$
375
                   
                           
Financial assets at fair value:
                         
Cash and cash equivalents
   
2,085
     
2,085
     
     
 
Total
 
$
2,085
   
$
2,085
   
$
   
$
 
                                 
Financial liabilities carried at historical proceeds:
                               
Current portion of long-term debt
 
$
457
                         
Long-term debt, net of current portion
   
137,150
                         
Total
 
$
137,607
                         
 
 
12

 
 
(9) Preferred stock
 
As of December 31, 2009, the Company had one class of undesignated preferred stock authorized with no shares issued or outstanding. The Board of Directors of the Company may designate and issue preferred stock in one or more series. The Board of Directors can fix the rights, preferences and privileges of the shares of each series and any of its qualifications, limitations or restrictions.
 
(10) Related-party transactions
 
The Company has property lease agreements with certain employees. The Company incurred related rent expense of $76 and $92 for the three months ended December 31, 2008 and 2009, respectively, and $160 and $185 for the six months ended December 31, 2008 and 2009, respectively. During the three months ended December 31, 2009, certain employees with whom the Company had such lease agreements ceased employment with the Company.  As such, there were no remaining future obligations outstanding at December 31, 2009 with related parties.
 
(11) Income taxes
 
The Company’s effective tax rate was 39.0% and 37.6% for the three months ended December 31, 2008 and 2009, respectively, and 39.5% and 37.6% for the six months ended December 31, 2008 and 2009, respectively. The decrease in the effective tax rate in the three months and six months ended December 31, 2009, as compared to the same periods in the prior year was attributable to lower income subject to U.S. Federal income tax, which carries a higher tax rate than income subject to Canadian income taxes.

At December 31, 2009, there were no material unrecognized tax benefits. In addition, there were no accruals for the payment of interest and penalties related to income tax liabilities at December 31, 2009. The Company recognizes potential interest and penalties related to unrecognized tax benefits in income tax expense. As of December 31, 2009, the Company has open tax years for Federal purposes back to June 2005. For state purposes, the open years typically date back to June 2006, although some states remain open back to June 2005.

(12) Commitments and contingencies
 
The Company is involved in various matters of litigation arising in the normal course of business. Although the ultimate liability from existing or potential claims cannot be ascertained, management does not anticipate that any related outcomes would have a materially adverse effect on the Company’s financial position, operating results or cash flows.
 
(13) Subsequent Events
 
The Company evaluated all events and transactions that occured from December 31, 2009 through February 2, 2010.  Effective January 22, 2010, the Company entered into a Confidential Settlement Agreement and Release, and a Confidential Patent Settlement Agreement and Release, with a competitor and its affiliated parties, which agreements settled all claims, disputes and related matters with prejudice.  As a result of such settlement and related legal costs, the Company recognized an additional liability of $350,000 and charged the amount against selling, general, and administrative costs in the three months ended December 31, 2009.  The parties agreed that the other terms included in these agreements are confidential.  However, we do not believe that the other settlement terms are material to the Company’s financial position, operating results or cash flows.
 
13

 Item 2.
Management’s Discussion and Analysis of Financial Condition and Results of Operations (Dollars in thousands, except share and per share data)
 
Forward Looking Statements
 
This Quarterly Report on Form 10-Q (Form 10-Q) contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In particular, statements contained in the Form 10-Q, including but not limited to, statements regarding the Company’s future results of operations and financial position, business strategy and plan prospects, projected revenue or costs and objectives of management for future operations, are forward-looking statements. These statements relate to the Company’s future plans, objectives, expectations and intentions and may be identified by words such as “may,” “will,” “should,” “expects,” “plans,” “anticipate,” “intends,” “target,” “projects,” “contemplates,” “believe,” “estimates,” “predicts,” “potential,” and “continue,” or the negative of these terms or other similar words. These statements are only predictions. We have based these forward looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, results of operations and financial condition. The outcome of the events described in these forward looking statements is subject to risks, uncertainties and other factors described in “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” elsewhere in this Quarterly Report on Form 10-Q and in our Annual Report on Form 10-K for the year ended June 30, 2009. Accordingly, you should not rely upon forward looking statements as predictions of future events. We cannot assure you that the events and circumstances reflected in the forward looking statements will be achieved or occur, and actual results could differ materially from those projected in the forward looking statements. The forward looking statements made in this Quarterly Report on Form 10-Q relate only to events as of the date on which the statements are made. We undertake no obligation to update any forward looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events.
 
Overview
 
The Company, through its operating subsidiaries, sells more than 40,000 products sourced from over 1,500 manufacturers to over 71,000 customers, as well as provides consultative services to customers in the highly fragmented animal health products industry. Products the Company distributes include pharmaceuticals, vaccines, parasiticides, diagnostics, capital equipment, sanitizers, devices, supplies, and dairy lagoon treatment systems. The Company’s principal customers are veterinarians, production animal operators and animal health product retailers. The Company’s strategy is to become the leading worldwide provider of animal health products and services in the production animal and companion animal health products markets through (i) organic growth, (ii) expansion of its sales of proprietary products, (iii) improved operational efficiencies, and (iv) select acquisitions.

 
14

 
 
 
Key factors and trends that have affected and the Company believes will continue to affect its operating results include:

·
Fluctuations in commodity prices;

·
Overall growth or contraction in the dairy industry;

·
Consolidation by the Company's customers in the dairy industry;

·
Increased focus on companion animal customers;

·
Changes in customer preferences; and

·
The impact of general economic trends on the Company's business.
  
The Company generates revenue from customers in three ways. Over 97% of the Company’s revenue is generated through “buy/sell” transactions. The remainder comes from consignment and agency transactions. In the “buy/sell” transactions, the Company takes title to the inventory from its manufacturers. The Company sells products to customers and invoices them. “Buy/sell” transactions are advantageous to the Company over other sales methods because the Company takes title to the inventory and is able to promote these products on behalf of manufacturers and effectively manage the pricing and distribution of these products. For consignment sales, the Company does not take title to the product, but it does stock and ship product to and invoice the customer. For agency sales, the Company transmits orders from its customers to its manufacturers. The manufacturer ships the product directly to the Company’s customers and compensates the Company with a commission payment for handling the order from the customer and providing customer service. Manufacturers may occasionally switch between the “buy/sell” and agency methods for particular products. Currently and for the past three fiscal years, only one product with material sales has been treated as a consignment sale.
 
For more information on the Company’s business, see the Company’s Annual Report on Form 10-K.

Results of Operations
 
The following table summarizes the historical results of operations for the three and six months ended December 31, 2008 and 2009, in dollars and as a percentage of net sales. The Company’s gross profit may not be comparable to other entities, since some entities include all of the costs related to their distribution network in cost of goods sold and others, like us, report non-direct costs instead in selling, general, and administrative expenses, and salaries, wages, commissions, and related benefits.
 
 
15

 
 
Summary consolidated results of operations table
 
 
  
Three Months Ended
December 31,
   
Six Months Ended
December 31,
 
(in thousands, except number of representatives)
  
2008
   
2009
   
2008
   
2009
 
Net sales
  
$
184,477
   
$
170,487
   
$
353,500
   
$
331,816
 
Direct cost of products sold (excludes depreciation and amortization)
  
 
152,209
     
141,071
     
290,932
     
276,454
 
                                 
Gross profit
  
 
32,268
     
29,416
     
62,568
     
55,362
 
                                 
Selling, general, and administrative expenses (includes salary, wages, commission, and related benefits)
  
 
24,397
     
23,540
     
50,015
     
46,328
 
Depreciation and amortization
  
 
2,054
     
2,022
     
4,130
     
4,000
 
                                 
Operating income
  
 
5,817
     
3,854
     
8,423
     
5,034
 
Other income (expense):
  
                             
Interest expense
  
 
(2,289
)
   
(2,068
)
   
(4,623
)
   
(4,579
)
Other income
  
 
189
     
166
     
418
     
300
 
                                 
Income before income taxes
  
 
3,717
     
1,952
     
4,218
     
755
 
Income tax expense
  
 
(1,448
)
   
(734
)
   
(1,665
)
   
(284
)
                                 
Net income
  
$
2,269
   
$
1,218
   
$
2,553
   
$
471
 
                                 
Net sales
  
 
100.0
%
   
100.0
%
   
100.0
%
   
100.0
%
Direct cost of products sold (excludes depreciation and amortization)
  
 
82.5
%
   
82.7
%
   
82.3
%
   
83.3
%
                                 
Gross profit
  
 
17.5
%
   
17.3
%
   
17.7
%
   
16.7
%
                                 
Selling, general, and administrative expenses (includes salary, wages, commission, and related benefits)
  
 
13.2
%
   
13.8
%
   
14.1
%
   
14.0
%
Depreciation and amortization
  
 
1.1
%
   
1.2
%
   
1.2
%
   
1.2
%
                                 
Operating income
  
 
3.2
%
   
2.3
%
   
2.4
%
   
1.5
%
Other income (expense)
  
                             
Interest expense
  
 
(1.3
)%
   
(1.3
)%
   
(1.3
)%
   
(1.4
)%
Other income
  
 
0.1
%
   
0.1
%
   
0.1
%
   
0.1
%
                                 
Income before income taxes
  
 
2.0
%
   
1.1
%
   
1.2
%
   
0.2
%
Income tax expense
  
 
(0.8
)%
   
(0.4
)%
   
(0.5
)%
   
(0.1
)%
                                 
Net income
  
 
1.2
%
   
0.7
%
   
0.7
%
   
0.1
%
                                 
Other data:
  
                             
Field sales representatives
  
 
227
     
216
     
227
     
216
 
 
Three months ended December 31, 2009 compared to three months ended December 31, 2008
 
Net sales.  Net sales decreased $13,990, or 7.6%, to $170,487 for the three months ended December 31, 2009, from $184,477 for the three months ended December 31, 2008. The decrease in net sales was primarily attributable to lower spending by production animal customers whose profits have been constrained by fluctuating commodity prices and the general economic slowdown. The number of field sales representatives decreased to 216 as of December 31, 2009, from 227 as of December 31, 2008, primarily as a result of consolidation of underperforming territories.

 
16

 
 
Gross profit.  Gross profit decreased $2,852, or 8.8%, to $29,416 for the three months ended December 31, 2009, from $32,268 for the three months ended December 31, 2008. Gross profit as a percentage of sales was 17.3% for the three months ended December 31, 2009, compared to 17.5% for the three months ended December 31, 2008. The decrease in gross profit resulted from the decline in sales combined with lower gross profit margins driven by declines in manufacturer rebates.
 
Selling, general, and administrative expenses. Selling, general, and administrative expenses decreased to $23,540 for the three months ended December 31, 2009, from $24,397 for the three months ended December 31, 2008. The decrease was primarily the result of a decrease in variable selling and distribution expenses driven by lower sales volume combined with cost reduction efforts. The fixed nature of certain expenses such as salaries, rent, and computer related costs, together with the $350 accrual for settlement and related legal costs drove a slight increase in selling, general and administrative expenses as a percent of sales from 13.2% for the three months ended December 31, 2008, to 13.8% for the three months ended December 31, 2009.
 
Depreciation and amortization. Depreciation and amortization decreased slightly from $2,054 for the three months ended December 31, 2008, to $2,022 for the three months ended December 31, 2009. The decrease results primarily from lower amortization of intangible assets driven by certain noncompete agreements reaching the conclusion of their useful lives.
 
Other expenses. Other expenses decreased $198, or 9.4%, to $1,902 for the three months ended December 31, 2009, from $2,100 for the three months ended December 31, 2008. The decrease in other expenses was due to a decrease in interest expense of $221 to $2,068 in the three months ended December 31, 2009, as compared to $2,289 in the three months ended December 31, 2008. This decrease was due to lower interest rates than in the prior year.
 
Income tax expenses. Income tax expense decreased $714, or 49.3%, to $734 for the three months ended December 31, 2009, from $1,448 for the three months ended December 31, 2008. The effective tax rate was 37.6% and 39.0% for the three months ended December 31, 2009 and 2008, respectively.  This decrease in the effective tax rate was attributable to lower income subject to U.S. Federal income tax, which carries a higher tax rate than income subject to Canadian income taxes.

Six months ended December 31, 2009 compared to six months ended December 31, 2008
 
Net sales. Net sales decreased $21,684, or 6.1%, to $331,816 for the six months ended December 31, 2009, from $353,500 for the six months ended December 31, 2008. The decrease in net sales was primarily attributable to lower spending by production animal customers whose profits have been constrained by fluctuating commodity prices and the general economic slowdown.  The number of field sales representatives decreased to 216 as of December 31, 2009, from 227 as of December 31, 2008 , as a result of consolidation of underperforming territories.
 
Gross profit. Gross profit decreased $7,206, or 11.5%, to $55,362 for the six months ended December 31, 2009, from $62,568 for the six months ended December 31, 2008. Gross profit as a percentage of sales was 16.7% for the six months ended December 31, 2009, compared to 17.7% for the six months ended December 31, 2008. The decrease in gross profit resulted from the decline in sales combined with lower gross profit margins driven by declines in manufacturer rebates.

Selling, general, and administrative expenses. Selling, general, and administrative expenses decreased $3,687, or 7.4%, to $46,328 for the six months ended December 31, 2009, from $50,015 for the six months ended December 31, 2008. The decrease was primarily the result of a decrease in variable selling and distribution expenses driven by lower sales volume combined with cost reduction efforts, partially offset by the $350 accrual for settlement and related legal costs. These factors drove a slight decrease in selling, general and administrative expenses as a percent of sales from 14.1% for the six months ended December 31, 2008, to 14.0% for the six months ended December 31, 2009.
 
Depreciation and amortization. Depreciation and amortization decreased from $4,130 for the six months ended December 31, 2008, to $4,000 for the six months ended December 31, 2009. The decrease results from lower amortization of intangible assets driven by certain noncompete agreements reaching the conclusion of their useful lives.
 
Other expenses. Other expenses increased $74, or 1.8%, to $4,279 for the six months ended December 31, 2009, from $4,205 for the six months ended December 31, 2008. The increase in other expenses was primarily due to a decrease in other income of $118 to $300 in the six months ended December 31, 2009, as compared to $418 in the six months ended December 31, 2008. This decrease in other income was primarily due to $86 of lower gains on the sale of equipment than in the prior year.
 
 
17

 
 
Income tax expenses. Income tax expense decreased $1,381, or 82.9%, to $284 for the six months ended December 31, 2009, from $1,665 for the six months ended December 31, 2008. The effective tax rate was 37.6% and 39.5% for the six months ended December 31, 2009 and 2008, respectively. This decrease in the effective tax rate was attributable to lower income subject to U.S. Federal income tax, which carries a higher tax rate than income subject to Canadian income taxes.
 
Liquidity and Capital Resources

The Company’s primary sources of liquidity are cash flows generated from operations and borrowings under the Company’s revolving credit facility. Funds are expended to provide working capital that enables the Company to maintain adequate inventory levels to promptly fulfill customer needs and expand operations. The Company expects its capital resources to be sufficient to meet anticipated cash needs for at least the next twelve months, and it expects cash flows from operations to be sufficient to reduce outstanding borrowings under the Company’s revolving credit agreement.
 
Operating activities.  For the six months ended December 31, 2009, net cash used for operating activities was $7,377, and was attributable to $471 in net income, $5,573 of non-cash costs, and a $221 change in deferred income taxes, all offset by an increase in working capital of $13,642. The non-cash costs included $4,000 of depreciation and amortization, $520 of debt issue cost amortization, $620 of amortization of loss on settlement of interest rate swap agreements, $203 of bad debt expense, and $245 of stock compensation expenses. The change in working capital included an increase in accounts receivable of $8,792 and an increase in inventory of $12,139, both partially offset by an increase in accounts payable of $7,470.  The increase in accounts receivable resulted from strong sales at the close of the quarter that converted to cash early in the third quarter. The increase in inventory was due to inventory purchases near the close of the quarter in advance of manufacturer price increases.  This increase in inventory drove the corresponding increase in accounts payable. While accounts receivable and inventory levels as a percentage of sales were higher at December 31, 2009, the Company expects to manage these balances back to historical norms.
 
For the six months ended December 31, 2008, net cash provided by operating activities was $1,858, and was attributable to $2,553 in net income and $5,074 of non-cash costs offset by an increase in working capital of $4,892 and a change in deferred income taxes of $877. The non-cash costs included $4,130 of depreciation and amortization, $338 of debt issue cost amortization, and $684 of stock compensation expenses. The change in working capital included an increase in accounts receivable of $6,772 and an increase in inventory of $2,001, both partially offset by an increase in accounts payable of $2,374 and a decrease in income tax receivables/payables of $1,117.  The increase in accounts receivable resulted from strong sales at the close of the quarter that converted to cash early in the third quarter.  The increase in inventory was due to inventory purchases near the close of the quarter in advance of manufacturer price increases.  This increase in inventory drove the corresponding increase in accounts payable.  The decrease in income tax receivables/payables results from the timing of income tax payments.
 
Investing activities.   For the six months ended December 31, 2009, net cash used for investing activities was $1,271, and was primarily attributable to $1,229 of purchases of property, plant, and equipment.
 
For the six months ended December 31, 2008, net cash used for investing activities was $3,918, and was primarily attributable to $2,825 in cash payments to certain selling stockholders of Kane for Kane’s achievement of certain performance targets and $1,751 of purchases of property, plant and equipment, partially offset by $301 of changes in notes receivable and $284 of proceeds from the sale of equipment.
 
Financing activities.   For the six months ended December 31, 2009, net cash provided by financing activities was $8,108, and was primarily attributable to net borrowings on the revolving credit facility totaling $17,308, partially offset by an unfavorable change in overdraft balances of $2,915, principal payments on other debt totaling $2,874, and the settlement of liabilities related to terminated interest rate swap agreements totaling $3,348.
 
For the six months ended December 31, 2008, net cash provided by financing activities was $7,161, and was primarily attributable to a change in overdraft balances of $4,759 and net borrowings from revolving credit facilities totaling $3,076, partially offset by $635 of repayments of long-term debt.
 
Capital resources.  In August 2007, the Company entered into a new $44,550 first lien term loan and with borrowings thereunder paid in full the $44,550 balance of our then existing $45,000 first lien term loan. The $44,550 first lien term loan matures on May 31, 2011 and bears interest at an annual rate equal to LIBOR plus 2.0%, which is paid quarterly. Borrowings are collateralized by a first priority interest in and lien on all of the Company’s assets.

 
18

 

In October 2007, the revolving credit facility (the Revolver) was amended to a $135,000 facility, which matures on June 30, 2010. The amended Revolver included a $10,000 overcollateralization first drawn sub-limit that amortizes and expired on March 31, 2009. The outstanding borrowings under the $10,000 overcollateralization first drawn sub-limit bore interest at the rate of 0.75% above the rate as defined per the terms of the September 2006 Revolver amendment. The outstanding borrowings under the Revolver’s base $135,000 facility bore interest at the rate defined per the terms of the September 2006 Revolver amendment.

In May 2009, the Revolver was amended to a $130,000 facility, with maturity on the earlier of June 30, 2012, or 60 days prior to the final extended maturity date of the Term Note, which currently matures on May 31, 2011. The outstanding borrowings under the amended facility bear interest through July 20, 2009, at LIBOR plus 3.50% for U.S. borrowings and CDOR Rate plus 1% for Canadian borrowings, and thereafter at rates based upon the Company’s Leverage Ratio as defined in the amended Revolver with LIBOR-based rates ranging from LIBOR and CDOR Rate plus 3.00% to LIBOR and CDOR Rate plus 3.75%, and with Prime-based rates ranging from U.S. Prime and Canadian Prime Rate plus 0.50% to U.S. Prime and Canadian Prime Rate plus 1.25%. Debt issue costs of $1,098 resulting from this extension were capitalized and are being amortized over the remaining term of the Revolver utilizing the straight-line method, which approximates the effective interest method.  Borrowings remain collateralized by a first priority interest in and lien on all of the Company’s assets. At December 31, 2009, the Company’s availability under the Revolver totaled $29,069.

As of December 31, 2009, the interest rates for the Revolver ranged from 3.80% to 4.25%, and the interest rate for the first lien term loan was 2.25%. Additionally, the Company is required to pay a commitment fee on the daily unused amount of the Revolver at a per annum rate of 0.50%. The credit agreements contain certain covenants that, among other things, restrict our ability to incur additional indebtedness, make certain payments, sell assets, enter into certain transactions with affiliates and create liens. Moreover, certain of these agreements require us to maintain specified financial ratios. The most restrictive covenant relates to the creation or assumption of additional indebtedness. The Company was in compliance with all financial covenants at December 31, 2009.

The Company has utilized cash flow hedge accounting and used derivative financial instruments to effectively convert a portion of its variable-rate debt to fixed-rate debt. Based upon interest rates, in order to reduce cash interest expense over the last three quarters of fiscal 2010, the Company elected to terminate both of its interest rate swap agreements as of September 30, 2009.

The Company entered into a $43,000 notional value swap transaction with a financial institution effective April 18, 2007. The Company received a floating rate based on LIBOR and paid a fixed rate of 4.95%. The swap agreement had an original termination date of June 28, 2010. On September 30, 2009, the Company terminated the swap agreement, and the fair value of this swap was a net liability of $1,511 on that date. This liability was paid in October 2009.

The Company entered into a $52,000 million notional value swap transaction with a financial institution effective April 18, 2007. The Company received a floating rate based on LIBOR and paid a fixed rate of 4.95%. The swap agreement had an original termination date of May 7, 2010. On September 30, 2009, the Company terminated the swap agreement, and the fair value of this swap was a net liability of $1,837 on that date. This liability was paid in October 2009.
 
Swap agreement fair values are recorded on the consolidated balance sheet as a component of current portion of long-term debt. The fair values of the interest rate swap agreements were estimated based on current settlement prices and quoted market prices of comparable contracts. The Company calculated no ineffectiveness on both interest rate swap agreements at their termination on September 30, 2009. At December 31, 2009, an unrealized loss of $1,016, net of taxes of $677, is recorded on the consolidated balance sheet as accumulated other comprehensive income (loss). This unrealized loss will be amortized to interest expense over the remaining terms of the original swap agreements.
 
The net receipts or payments from the interest rate swap agreements were recorded in interest expense. During the three months ended December 31, 2008, changes in the fair values of interest rate swap agreements totaled $(2,320). During the six months ended December 31, 2008 and 2009, changes in the fair value of interest rate swap agreements totaled $(2,218) and $572, respectively. The Company reclassified $447 during the three months ended December 31, 2008, and $968 and $1,047, respectively, during the six months ended December 31, 2008 and 2009, from accumulated other comprehensive income (loss) to interest expense. 
 
 
19

 
 
 
Contractual Obligations
 
As of December 31, 2009, there were no material changes in the Company’s contractual obligations as disclosed in the Company’s Annual Report on Form 10-K.
 
Off-Balance Sheet Arrangements
 
As of December 31, 2009, the Company did not have any off-balance sheet arrangements other than the operating lease commitments in the contractual obligations table as disclosed in the Company’s Annual Report on Form 10-K.
 
Recent Accounting Pronouncements
 
A recent pronouncement by the FASB defines fair value, establishes a framework for measuring fair value in accordance with GAAP, and expands disclosures about fair value measurements. The provisions of this pronouncement were adopted on a prospective basis for financial instruments in the first quarter of fiscal 2009 and had no impact upon the Company’s consolidated financial statements. Those provisions relate to financial assets and liabilities carried at fair value and fair value disclosures related to financial assets and liabilities. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.  The provisions of the pronouncement for nonfinancial assets and nonfinancial liabilities became effective for the Company in the first quarter of fiscal 2010 and had no impact upon the Company ’ s consolidated financial statements.
 
A recent FASB pronouncement establishes principles and requirements for how an acquirer in a business combination recognizes and measures in its financial statements the identifiable assets acquired, the liabilities assumed, and any controlling interest; recognizes and measures the goodwill acquired in the business combination or a gain from a bargain purchase; and determines what information to disclose to enable users of the financial statements to evaluate the nature and financial effects of the business combination. The pronouncement became effective for the Company in the first quarter of fiscal 2010. The impact that the pronouncement will have on future consolidated financial statements will vary with each future acquisition.
 
In June 2009, the FASB released a Codification, which establishes the FASB Accounting Standards Codification as the source of authoritative accounting principles recognized by the FASB to be applied in the preparation of financial statements in conformity with GAAP. This Codification explicitly recognizes rules and interpretive releases of the SEC under federal securities laws as authoritative GAAP for SEC registrants. The Codification became effective September 15, 2009, and did not have an impact upon the Company’s consolidated financial statements.
 
 
20

 
 
 Item 3.
Quantitative and Qualitative Disclosures About Market Risk

Exposure to Interest Rates
 
The Company is exposed to certain market risks arising from transactions that are entered into in the normal course of business. As part of the Company’s financial risk management program, it has used certain derivative financial instruments to manage these risks. The Company does not engage in financial transactions for speculative purposes and therefore holds no derivative instruments for trading purposes. The Company’s exposure to market risk for changes in interest rates relates to variable interest rates on borrowings under the Company’s credit agreements. At December 31, 2009, $137.6 million of the Company’s debt remained subject to market risk for changes in interest rates. If the weighted average interest rate on the Company’s remaining variable rate indebtedness rose 31 basis points (a 10.0% change from the calculated weighted average interest rate as of December 31, 2009), assuming no change in the Company’s outstanding balance under its revolving credit facility and Term Note, the Company’s annualized income before taxes and cash flows from operating activities would decline by approximately $0.4 million. If the weighted average interest rate on the Company’s remaining variable rate indebtedness decreased 31 basis points (a 10.0% change from the calculated weighted average interest rate as of December 31, 2009), assuming no change in the Company’s outstanding balance under its revolving credit facility and Term Note, the Company’s annualized income before taxes and cash flows from operating activities would increase by approximately $0.4 million.

Exposure to Exchange Rates

AHII's subsidiaries are located in Canada and Taiwan. Due to the relative low volume of payments made by AHII through these subsidiaries, the Company does not believe that it has significant exposure to foreign currency exchange risks. The Company currently does not use derivative financial instruments to mitigate foreign currency exchange risks. The Company continues to review this issue and may consider hedging certain foreign exchange risks through the use of currency futures or options in future years.
 
Item 4.
Controls and Procedures

Our management, with the participation of our chief executive officer and chief financial officer, evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2009. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (Exchange Act), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of December 31, 2009, our chief executive officer and chief financial officer concluded that, as of such date, the Company’s disclosure controls and procedures were effective at the reasonable assurance level.
 
No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the fiscal quarter ended December 31, 2009 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
 
 
21

 
 
PART II. OTHER INFORMATION
 
 Item 1.
Legal Proceedings
 
From time to time, we are a party to legal proceedings and claims arising in the ordinary course of business. We are not currently aware of any such proceedings or claims that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations.
 
 Item 1A.
Risk Factors
 
Not Applicable.
 
 Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds
 
Not Applicable.
 
 Item 3.
Defaults Upon Senior Securities
 
None.
 
 Item 4.
Submission of Matters to a Vote of Security Holders
 
The Company held its 2009 Annual Meeting of Stockholders on November 17, 2009.  On the record date, 24,329,670 shares of our common stock were entitled to vote.  At the meeting, 20,953,755 shares were represented in person or by proxy.  
 
The first proposal was considered to approve an amendment and restatement of the 2007 Stock Option and Incentive Plan.  The proposal passed with 15,449,525 votes for, and 22,300 votes withheld.  The second proposal was considered to elect three Class III members to the Board of Directors as directors whose term will expire in 2012. The following individuals were elected as Class III directors:
 
Name
 Votes For
Votes Withheld
David W. Biegler 
 18,188,477
 2,765,278
Jerry W. Pinkerton        
 18,191,742
 2,762,013
Brandon White
18,411,902
2,541,853
 
 Item 5.
Other Information
 
None.
 
Item 6.
Exhibits

     
Number
  
Description
   
31.1
  
Rule 13a-14(a)/15d-14(a) Certification, executed by James C. Robison, Chairman, President and Chief Executive Officer.
   
31.2
  
Rule 13a-14(a)/15d-14(a) Certification, executed by William F. Lacey, Senior Vice President and Chief Financial Officer.
   
32.1*
  
Section 1350 Certifications, executed by James C. Robison, Chairman, President and Chief Executive Officer, and William F. Lacey, Senior Vice President and Chief Financial Officer.
 
*
This certification shall not be deemed “filed” for purposes of Section 18 of the Securities Act of 1934, or otherwise subject to the liability of that Section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934.
   
 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
     
   
Animal Health International, Inc.
(Registrant)
   
Date: February 2, 2010
 
/s/ William F. Lacey
   
William F. Lacey
   
Senior Vice President and Chief Financial Officer
   
(Principal Financial and Accounting Officer)